| Literature DB >> 30862736 |
Yingjiao Cao1,2, Qiong Yang2, Hui Deng1,2, Jinyi Tang3, Jiancong Hu4, Huanliang Liu4, Min Zhi4, Linsen Ye5, Bin Zou6, Yongdong Liu7, Lai Wei6, Dmitry I Gabrilovich2,8, Haikun Wang3, Jie Zhou9,2,10.
Abstract
Disruption of mucosal immunity plays a critical role in the pathogenesis of inflammatory bowel disease, yet its mechanism remains not fully elucidated. Here, we found that activating transcription factor 3 (ATF3) protects against colitis by regulating follicular helper T (TFH) cells in the gut. The expression of ATF3 in CD4+ T cells was negatively correlated with the severity of ulcerative colitis in clinical patients. Mice with ATF3 deficiency in CD4+ T cells (CD4 cre Atf3 fl/fl ) were much more susceptible to dextran sulfate sodium-induced colitis. The frequencies of TFH cells, not other T cell subsets, were dramatically decreased in Peyer's patches from CD4 cre Atf3 fl/fl mice compared with Atf3 fl/fl littermate controls. The defective TFH cells significantly diminished germinal center formation and IgA production in the gut. Importantly, adoptive transfer of TFH or IgA+ B cells caused significant remission of colitis in CD4 cre Atf3 fl/fl mice, indicating the TFH-IgA axis mediated the effect of ATF3 on gut homeostasis. Mechanistically, B cell lymphoma 6 was identified as a direct transcriptional target of ATF3 in CD4+ T cells. In summary, we demonstrated ATF3 as a regulator of TFH cells in the gut, which may represent a potential immunotherapeutic target in colitis.Entities:
Keywords: Peyer’s patches; activating transcription factor 3; colitis; follicular helper T cell; intestinal mucosal immunity
Mesh:
Substances:
Year: 2019 PMID: 30862736 PMCID: PMC6442638 DOI: 10.1073/pnas.1818164116
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205